INTRODUCTION
============

Cardiac power (CP) is defined as the product of simultaneously measured mean arterial pressure (MAP) and cardiac output.[@B1][@B2][@B3][@B4] By integrating pressure and flow parameters of the cardiovascular system, it is, therefore, an estimate of cardiac function.[@B1] In particular, it represents the energy exerted by the left ventricle (LV) to pump blood into the systemic vasculature. Previous studies have shown that cardiac power index (CPI) can be a strong predictor of mortality in chronic heart failure and cardiogenic shock patients.[@B4][@B5][@B6][@B7][@B8][@B9]

Given the high 1-year mortality rate after transcatheter aortic valve replacement (TAVR), according to the Transcatheter Valve Therapy (TVT) Registry, better risk prediction tools in this population are needed.[@B10] Previously, we demonstrated an association between resting CP and survival after TAVR,[@B11] which is the primary treatment of choice in high risk patients with severe aortic stenosis.[@B12] However, MAP does not accurately represent mean systolic left ventricular pressure in patients with aortic stenosis due to the trans-valvular gradient across the aortic valve, which adds to the total LV afterload. Accordingly, we hypothesized that transvalvular gradient-adjusted CP (GCP) might help to better predict survival post TAVR over CP alone.

In this study, we sought to evaluate the relationship between GCP obtained by three different methods and 1-year mortality in patients with severe aortic stenosis who underwent TAVR.

MATERIALS AND METHODS
=====================

Study population
----------------

This study was conducted as a multicenter retrospective analysis of patients with severe symptomatic aortic stenosis who underwent TAVR between January 1, 2012, and June 20, 2017 at Mayo Clinic hospitals at Phoenix, Arizona; Rochester, Minnesota; and Jacksonville, Florida. The study conformed to institutional guidelines and those of the American Physiological Society. The study included patients aged ≥18 years with symptomatic severe aortic stenosis who underwent TAVR with either balloon expandable or self-expanding aortic valve prostheses, who had a transthoracic echocardiogram (TTE) performed within 2 months of TAVR, and who had follow-up data at 1 year after treatment. Exclusion criteria included patients without follow-up data and patients with moderate to severe aortic regurgitation. Of 1070 patients who underwent TAVR, 95 patients were excluded due to a lack of follow-up data at 1 year, no TTE within 60 days of the index procedure, and refusal to approve research authorization ([Supplementary Fig. 1](#S7){ref-type="supplementary-material"}, only online). The Institutional Review Board (IRB) of the Mayo Clinic approved the research protocol (IRB number: 17-010424), and all patients provided research authorization to utilize the medical information. Valve clinic coordinators were responsible for obtaining follow-up data by contacting the patient or the family, and some data were collected from medical provider records at an outside facility. The primary outcome was all-cause mortality at 1 year after TAVR.

Baseline variables
------------------

Pre-procedural variables included age; sex; race; comorbidities, such as diabetes mellitus, hypertension, myocardial infarction, stroke, transient ischemic attack, infective endocarditis, peripheral artery disease, atrial fibrillation/flutter, carotid artery stenosis, or chronic obstructive pulmonary disease; history of smoking, coronary artery bypass graft surgery (CABG), or carotid artery stenting/endarterectomy; heart failure within 2 weeks; New York Heart Association class for the previous 2 weeks; cardiogenic shock within 2 weeks; cardiogenic shock within 24 hours; permanent pacemaker implantation; dialysis; home oxygen use; left main stenosis ≥50%; porcelain aorta; vascular access site; type of TAVR valve; serum albumin level; elective versus emergency procedure; type of anesthesia; presence of a mechanical assist device prior to initiation of TAVR; and Society of Thoracic Surgeons-Predicted Risk of Operative Mortality (STS-PROM) score by chart review based on definitions developed by the TVT registry.[@B13] We used a manual sphygmomanometer to calculate blood pressure (BP) during TTE according to American College of Cardiology (ACC) guidelines and the following formula: \[systolic BP+(2×diastolic BP)\]/(3 mm of Hg to calculate MAP).[@B14]

Echocardiography and its variables
----------------------------------

We used standard ultrasound scanners (Philips iE33; Phillips Medical Systems, Andover, MA, USA; GE Vivid E9, GE Healthcare, Milwaukee, WI, USA) to perform comprehensive Doppler and 2-dimensional TTE on all the patients before undergoing TAVR. The guidelines of European Association of Echocardiography (EAE) and American Society of Echocardiography (ASE) were used to interpret the images. We used ProSolv Cardiovascular Analyzer 3.0 (ProSolv Cardiovascular Inc., Indianapolis, IN, USA) to make offline measurements of the TTE images.

The variables measured for the study included severity of mitral regurgitation, severity of tricuspid regurgitation, left ventricular ejection fraction (LVEF), aortic valve area (AVA), aortic valve systolic mean gradient (AVSMG), right ventricular systolic pressure (RVSP), and cardiac output. Mild, moderate, and severe regurgitation across mitral, tricuspid and aortic valves were assessed based on criteria set forth by the American Society of Echocardiography and Society for Cardiovascular Magnetic Resonance.[@B15] Simpson\'s biplane method of disks was used to measure LVEF.[@B16] The continuity equation was utilised to calculate the AVA and indexed to body surface area (AVAI). AVSMG was measured with the modified Bernoulli equation. These parameters were used to classify patients to have severe aortic stenosis and were defined as AVA ≤1 cm^2^, AVAI ≤0.6 cm^2^, and AVSMG ≥40 mm Hg or a peak velocity ≥4.0 m/s.[@B12][@B17] RVSP was calculated using Bernoulli\'s equation: 4(V2)+right atrial pressure, where V stands for the tricuspid regurgitant jet peak velocity and right atrial pressure was measured from the diameter of inferior vena cava and its respirophasic changes.[@B18] Cardiac output was calculated as \[left ventricular outflow tract (LVOT) diameter^2^×0.785×LVOT velocity time integral) (liters/minute), in which LVOT diameter was measured in a parasternal long axis view between aortic valve cusp bases and in systole.

CP was calculated as (MAP×cardiac output)/\[451×body surface area (BSA)\] (W/m^2^) and indexed to body surface area with the use of baseline pre-TAVR echocardiograms to measure CP (W/m^2^). GCP was calculated using three different methods: 1) CP1, adding aortic valve mean gradient (AVMG) to systolic BP; 2) CP2, adding aortic valve maximal instantaneous gradient to systolic BP (CP2); and 3) adding AVMG to MAP (CP3). Due to a lack of published literature on non-invasive assessment of mean left ventricular pressure in patients with aortic stenosis, we made the following assumptions while calculating gradient-adjusted CPI. We assumed that the addition of either mean (CP1) or maximal instantaneous gradient (CP2) across the aortic valve to systemic systolic pressure would likely reflect the true systolic pressure generated by the left ventricular. For the calculation of CP3, we assumed that the addition of mean gradient across the aortic valve to mean systemic pressure would likely reflect the mean left ventricular systolic pressure in one cardiac cycle.

Statistical analysis
--------------------

Survival analysis was performed using a step-up technique to identify cut-off values for CPI and gradient-adjusted CPI to recognize where the maximum mortality difference occurred.[@B19] The study cohort was divided accordingly into two groups using the cut-off values of 0.49, 0.59, 0.65, and 0.78 W/m^2^ for CP, CP1, CP2, and CP3, respectively. Continuous variables are shown as means±SDs, and categorical variables are presented as numbers and percentages. Baseline characteristics were compared using the t-test for categorical variables and chi-square or Fisher exact tests for continuous variables. Univariate analysis was performed to determine the relationship between baseline variables and all-cause mortality at 1 year with CP, CP1, CP2, and CP3. All variables with statistically significant associations noted in univariate logistic regression analysis were included in the multivariate survival analysis. Event rates for the study were calculated using the Kaplan-Meier method. Spearman correlation analysis was conducted to assess correlations among CP, CP1, CP2, and CP3.[@B20]

RESULTS
=======

The study\'s mean follow-up time was 378 days. The mean age of the patients was 81±9 years, and 59.04% were male. All of the baseline characteristics of the study are described in detail in [Table 1](#T1){ref-type="table"} and [Supplementary Tables 1](#S1){ref-type="supplementary-material"}, [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}, [4](#S4){ref-type="supplementary-material"} (only online). One-year mortality following the index procedure was 13.94% (141 patients). CP showed a modest relationship with mortality at 1 year. AUCs of 0.67, 0.65, 0.66, and 0.63 were achieved using CP, CP1, CP2, and CP3 respectively ([Table 2](#T2){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}). Receiver operating characteristics (ROC) curves analysis for individual parameters are shown in [Supplementary Fig. 2](#S8){ref-type="supplementary-material"} (only online). [Fig. 1](#F1){ref-type="fig"} demonstrates the ROC curves of all the parameters combined. All of the parameters show a significant association with the primary endpoint, with CP being the strongest ([Fig. 1](#F1){ref-type="fig"}). CPI in the deceased group was significantly lower than in the alive group (0.51±0.15 W/m^2^ vs. 0.6±0.16, *p*\<0.001). Gradient-adjusted CPI also showed a significant relationship with patient mortality. CP1, CP2, and CP3 were low in the deceased group: 0.60±0.16 vs. 0.69±0.19, 0.65±0.17 vs. 0.76±0.21, and 0.78±0.21 vs. 0.89±0.25, respectively, with *p*\<0.001. Patients in the deceased group had a higher prevalence of chronic lung disease, atrial fibrillation/flutter, mild to moderate and severe mitral valve regurgitation, moderate to severe and severe tricuspid valve regurgitation, higher RVSP, and a higher prevalence of patients on dialysis.

Survival score analysis was performed with a step up in the parameters with cut-offs of 0.49, 0.59, 0.65, and 0.78, which produced the maximum distance between the survival curves. Accordingly, the study was divided into groups based on the cut-off values ([Fig. 2](#F2){ref-type="fig"}). Unadjusted Kaplan-Meier survival curves are shown in [Fig. 3](#F3){ref-type="fig"} (*p*\<0.001).

A lower CP was associated with a higher 1-year mortality post-procedure (24.39% vs. 8.29%, *p*\<0.001).[@B11] Subgroup analysis was also performed excluding mitral regurgitation patients, given that the presence of significant mitral regurgitation may underestimate CP. The association remained statistically significant even in the subgroup analysis \[hazard ratio, 0.005; 95% confidence interval (CI), 0.001--0.036, *p*\<0.001\] ([Supplementary Figs. 3](#S9){ref-type="supplementary-material"} and [4](#S10){ref-type="supplementary-material"}, only online). Estimated 1-year mortality as a function of CP, CP1, CP2, and CP3 is shown in [Supplementary Fig. 5](#S11){ref-type="supplementary-material"} (only online).

Univariate logistic regression analysis results of all individual covariates are described in [Table 3](#T3){ref-type="table"}. Patients with moderate to severe chronic lung disease, requirement of home oxygen, presence of atrial fibrillation, heart failure within 2 weeks of index procedure, higher STS-PROM score, lower serum albumin, emergent TAVR, moderate to severe tricuspid regurgitation, elevated right ventricular systolic pressure, lower CPI, and requirement of dialysis conferred an elevated risk of all-cause mortality at 1 year. Multivariate cox regression analysis was performed with adjustment of baseline variables, including age, sex, race, history of stroke, percutaneous coronary intervention, CABG, peripheral artery disease, hypertension, diabetes mellitus, hemodialysis, HmO2 use, atrial fibrillation/flutter, STS-PROM score, serum albumin, mitral regurgitation, tricuspid regurgitation, RVSP, and AVSMG to estimate the independent associations of CP, CP1, CP2, and CP3 with 1-year mortality post TAVR. All the parameters showed an independent association with elevated 1-year mortality ([Table 4](#T4){ref-type="table"}).

Spearman correlation curves are illustrated in [Fig. 4](#F4){ref-type="fig"} to demonstrate the strength of the correlation between CP and CP1, CP2, and CP3. Spearman correlation coefficients between CP, CP1, CP2, CP3, and covariates of age, STS risk score, total albumin, RVSP, and AVSMG are described in [Supplementary Tables 5](#S5){ref-type="supplementary-material"} and [6](#S6){ref-type="supplementary-material"} (only online). Grouping data of all groups with the best survival cut-offs are shown in [Fig. 2](#F2){ref-type="fig"}. CP1, CP2, and CP3 showed no superiority compared to CP alone in predicting 1-year mortality post TAVR.[@B20]

DISCUSSION
==========

This retrospective cohort study of 975 patients showed that CP and GCP were strongly associated with all-cause mortality at 1 year in patients who underwent TAVR. Survival analysis at 1 year ([Supplementary Figs. 3](#S9){ref-type="supplementary-material"} and [4](#S10){ref-type="supplementary-material"}, only online) showed associations for all parameters with 1-year mortality. CP and GCP associations remained significant with the exclusion of mitral regurgitation patients and multivariate adjustment of baseline demographics, other co-morbidities, echocardiographic, laboratory, and pre-procedural variables. A sub-group analysis excluding mitral regurgitation was performed because cardiac output assessed by echocardiogram in this subgroup may not be accurate with a significant regurgitant volume. All parameters showed a statistical significance even in the subgroup analysis.

Obeying the fundamental Law of Conservation of Energy, the cardiac pump generates and imparts a continuous supply of hydraulic energy to prevent the cessation of circulation, owing to dissipation of energy in the vasculature.[@B21] Hence, the cardiac pump converts chemical energy into hydraulic energy in order to maintain a viable circulation.[@B22] The complex interaction of vascular compliance and resistance to flow, in addition to intravascular volume and cardiac filling pressures, requires a variable combining flow and pressure to predict outcomes.[@B23] CP output, which combines cardiac output and MAP, represents the ability of the heart to deliver hydraulic energy to maintain sufficient circulation, which, when indexed to BSA, gives CPI. Representing the LV expenditure to pump blood into the systemic vasculature, it provides a more accurate assessment of patient status.

The study\'s 1-year mortality was 13.84%, which is considerably lower than the US national average of 23.7% at 1 year.[@B10] The mean STS-PROM score was 8.24, compared to the STS/TVT registry score of 7.1 percent. Baseline variables associated with 1-year mortality included chronic lung disease, presence of atrial fibrillation, higher STS-PROM score, the requirement of home oxygen, heart failure within 2-weeks of index procedure, lower serum albumin, moderate to severe tricuspid regurgitation, emergent TAVR, elevated right ventricular systolic pressure, requirement of dialysis, and lower CP. These results corresponded to the results reported by the STS/TVT registry.[@B10] Spearman correlation analysis showed a significant association between CP and CP1, CP2, and CP3. ROC curves showed a significant association with 1-year mortality in the study patients ([Fig. 4](#F4){ref-type="fig"}). However, GCP (CP1, CP2, and CP3) was not superior to CPI in estimating mortality post-TAVR.

Previous studies have shown CP to predict outcomes in a variety of other conditions, such as acute coronary syndrome, cardiac arrhythmias, post percutaneous coronary interventions, and cardiogenic shock.[@B4][@B24][@B25][@B26] We previously demonstrated the potential benefit of measuring resting CP to risk stratify patients undergoing TAVR.11 We studied 975 patients retrospectively and divided them into two groups by identifying a cut-off value for CP and concluded that patients with low baseline CP (CP\<0.48 W/m^2^) had higher mortality after 1 year.

MAP, which is used to calculate CP, may not be an accurate reflection of LV afterload in patients with aortic stenosis, because of the presence of the trans-valvular gradient, which increases LV systolic pressure. Hence, we measured GCP by accounting for aortic valve mean gradient and aortic valve maximal instantaneous gradient. Integrating these measures may provide a more accurate assessment of the CP and could potentially risk stratify the patients undergoing TAVR. However, as the gradient-adjusted CPI did not show superiority when compared to CPI alone in predicting 1-year mortality post TAVR, MAP can be taken to measure the LV pressure to calculate CP.

The pathogenesis and prognoses of aortic stenosis and heart failure are interlinked. A large portion of patients in our cohort had worsening heart failure 2 weeks prior to the procedure. Resting CP for a hemodynamically stable average-sized adult is 1 W, can increase up to 6 W during exertion and stress, and is significantly diminished in chronic heart failure.[@B6] CP has also been shown to be a useful tool for prognostication in heart failure patients in previous studies.[@B27] This is likely attributable to decreasing cardiac functional reserve and aerobic capacity in older aged individuals, with greater reserve less likely to decline compared to low cardiac reserve.

We plan to conduct a subsequent study to evaluate the role of resting CP, peak stress CP, and ΔCP to assess relationship with short- and long-term mortality in patients with aortic stenosis undergoing TAVR, focusing on patients with low-flow low-gradient aortic stenosis.

There can be inherent limitations to a retrospective cohort study, such as study design, selection bias, unmeasured confounders, etc. Several factors, including prevalence of arrhythmias, medical conditions like obesity, and loading conditions, can also affect the accuracy of cardiac output assessed by Doppler echocardiography. A median time gap of 45 days was present before the index procedure and measurement of cardiac output, although, preferably, it should be measured on the same day before the procedure. Hence, it is uncertain whether there was a gradual decline in cardiac function until TAVR was performed. Variability in BP measurement, labile BPs, or temporarily high BPs because of "white coat hypertension" may overestimate/underestimate CP.

In conclusion, gradient-adjusted CPI does not show superiority over CPI alone in predicting 1-year mortality post TAVR. This is likely explained by attenuated CPI noted in patients with severe aortic stenosis. Therefore, incorporation of MAP (measured either invasively/non-invasively) during calculation of CPI without accounting for gradient pressure across the aortic valve would be sufficient for assessing pre-TAVR CPI and predicting mortality post-TAVR.

The abstract of this study was presented at EuroEcho 2019.
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###### Supplementary Table 1

Baseline Characteristics-Groups Classified Based on CP

###### Supplementary Table 2

Baseline Characteristics-Groups Classified Based on CP1

###### Supplementary Table 3

Baseline Characteristics-Groups Classified Based on CP2

###### Supplementary Table 4

Baseline Characteristics-Groups Classified Based on CP3

###### Supplementary Table 5

Spearman Correlation Coefficient between CP, CP1, CP2, CP3 and Other Continuous Co-Variates

###### Supplementary Table 6

*p* Values for Different Comparison Pairs

###### Supplementary Fig. 1

Flowchart depicting the patient recruitment for the analysis. TAVR, transcatheter aortic valve replacement; TTE, transthoracic echocardiogram.

###### Supplementary Fig. 2

ROC curves of 1-year mortality with (A) CP, (B) CP1, (C) CP2, and (D) CP3 values. AUC, area under the curve; CP, cardiac power; ROC, receiver operator curves.

###### Supplementary Fig. 3

Multivariate Cox regression analysis of 1-year mortality including all patients using (A) CP, (B) CP1, (C) CP2, and (D) CP3. CP, cardiac power; HR, hazard ratio; CI, confidence interval.

###### Supplementary Fig. 4

Univariate Cox regression analysis of 1-year mortality excluding mitral regurgitation patients using (A) CP, (B) CP1, (C) CP2, and (D) CP3. CP, cardiac power; HR, hazard ratio; CI, confidence interval.

###### Supplementary Fig. 5

Unadjusted estimated 1-year mortality with 97.5% pointwise confidence bands for (A) CP, (B) CP1, (C) CP2, and (D) CP3. CP, cardiac power; CI, confidence interval.

![ROC curves of 1-year mortality prediction with CP, CP1, CP2, and CP3 values. AUC, area under the curve; CP, cardiac power; ROC, receiver operator curves.](ymj-61-482-g001){#F1}

![Survival score analysis to identify cut-offs points for (A) CP, (B) CP1, (C) CP2, and (D) CP3. CP, cardiac power.](ymj-61-482-g002){#F2}

![Unadjusted Kaplan-Meier survival curves for (A) CP, (B) CP1, (C) CP2, and (D) CP3. CP, cardiac power.](ymj-61-482-g003){#F3}

![Spearman correlation graphs comparing CP with (A) CP1, (B) CP2, and (C) CP3. CP, cardiac power.](ymj-61-482-g004){#F4}

###### Baseline Characteristics

![](ymj-61-482-i001)

  Covariates                                                    Alive (n=840)   Deceased (n=135)   *p* value
  ------------------------------------------------------------- --------------- ------------------ -----------
  Age (yr)                                                      81±9            80±9               0.148
  Male sex (%)                                                  496 (59.04)     83 (61.48)         0.637
  Caucasian race                                                815 (97)        130 (96.3)         \<0.001
  Prior PCI                                                     305 (36.31)     48 (35.56)         0.923
  Prior CABG                                                    224 (26.67)     42 (31.11)         0.298
  Prior stroke                                                  76 (9.05)       20 (14.81)         0.043
  Prior PAD                                                     421 (50.12)     72 (53.33)         0.516
  Smoking history                                               24 (2.86)       4 (2.96)           1.000
  Hypertension                                                  714 (85)        114 (84.44)        0.896
  Diabetes mellitus                                             294 (35)        52 (38.52)         0.439
  History of infective endocarditis                             7 (0.83)        2 (1.48)           0.360
  Permanent pacemaker                                           131 (15.6)      25 (18.52)         0.378
  Previous implantable cardioverter device                      33 (3.9)        6 (4.44)           0.812
  History of transient ischemic attack                          74 (8.81)       16 (11.85)         0.262
  Carotid artery stenosis                                       155 (18.45)     32 (23.7)          \<0.001
  Carotid artery stenting/endarterectomy                        55 (6.55)       12 (8.89)          0.357
  Current dialysis                                              23 (2.74)       12 (8.89)          \<0.001
  Moderate to severe chronic lung disease                       258 (30.72)     63 (46.67)         \<0.001
  HmO~2~                                                        71 (8.45)       24 (17.78)         0.001
  Atrial fib/flutter                                            337 (40.12)     79 (58.52)         \<0.001
  Heart failure within 2 weeks                                  660 (78.57)     120 (88.89)        0.007
  NYHA class within 2 weeks                                                                        \<0.001
   I                                                            26 (3.1)        6 (4.44)           
   II                                                           178 (21.19)     27 (20)            
   III                                                          513 (61.07)     75 (55.55)         
   IV                                                           123 (14.64)     27 (20)            
  Cardiogenic shock within 24 hours                             3 (0.36)        0 (0)              0.999
  Left main stenosis ≥50%                                       105 (12.5)      22 (16.3)          0.217
  Proximal left anterior descending artery stenosis ≥70%        169 (20.12)     30 (22.22)         0.566
  Porcelain aorta                                               75 (8.93)       15 (11.11)         0.423
  STS risk score                                                8.03±5.16       9.59±5.11          0.001
  Total albumin                                                 4.14±0.38       4±0.46             \<0.001
  Vascular access site                                                                             0.076
   Femoral                                                      646 (76.9)      96 (71.11)         
   Trans-apical                                                 152 (18.1)      30 (22.22)         
   Trans-aortic                                                 29 (3.45)       5 (3.7)            
   Axillary                                                     5 (0.6)         4 (2.96)           
   Subclavian                                                   5 (0.6)         0 (0)              
   Trans-iliac                                                  3 (0.36)        0 (0)              
  Balloon expandable valve                                      656 (78.1)      102 (75.56)        0.505
  Elective procedure                                            796 (94.76)     122 (90.37)        0.049
  Anesthesia                                                                                       \<0.001
   Epidural anesthesia                                          1 (0.12)        0 (0)              
   General anesthesia                                           722 (85.95)     122 (90.37)        
   Moderate sedation                                            117 (13.93)     13 (9.63)          
  Mechanical assist device in place at start of the procedure                                      \<0.001
   None                                                         824 (98.10)     131 (97.04)        
   Catheter-based assist device                                 2 (0.24)        0 (0)              
   Intra-aortic balloon pump                                    14 (1.67)       4 (2.96)           
  Ejection fraction (%)                                         57.22±12.8      55.74±14.06        0.221
  Aortic valve area (mm^2^)                                     0.88±0.37       0.85±0.35          0.434
  Aortic valve systolic mean gradient (mm Hg)                   43.24±13.89     42.1±12.51         0.371
  Moderate to severe mitral valve regurgitation                 37 (4.4)        7 (5.18)           0.380
  Moderate to severe tricuspid valve regurgitation              58 (6.9)        21 (15.55)         \<0.001
  Moderate pulmonary regurgitation^\*^                          22 (2.62)       3 (2.22)           \<0.001
  Right ventricular systolic pressure (mm Hg)                   41.58±13.41     45.89±18.54        0.001
  CP                                                            0.60±0.16       0.51±0.15          \<0.001
  CP1                                                           0.69±0.19       0.60±0.16          \<0.001
  CP2                                                           0.76±0.21       0.65±0.17          \<0.001
  CP3                                                           0.89±0.25       0.78±0.21          \<0.001

PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; PAD, peripheral artery disease; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons; CP, cardiac power.

Data are presented as number (%) or mean±SD.

^\*^No patients had severe pulmonary regurgitation.

###### AUC Values for the Parameters

![](ymj-61-482-i002)

  Variable   AUC      AUC (95% CI)     Sensitivity   Specificity   Cut-off
  ---------- -------- ---------------- ------------- ------------- ---------
  CP         0.6702   0.6201--0.7203   0.7103        0.6738        0.49
  CP1        0.6542   0.6048--0.7037   0.6724        0.6549        0.59
  CP2        0.6645   0.6165--0.7125   0.6587        0.6739        0.65
  CP3        0.6328   0.5839--0.6817   0.6314        0.6357        0.78

AUC, area under the curve; CI, confidence interval; CP, cardiac power.

###### Univariate Logistic Regression Results of Baseline Variables on 1-Year Mortality

![](ymj-61-482-i003)

  Covariates                                                        Hazard ratio   95% CI lower   95% CI upper   *p* value
  ----------------------------------------------------------------- -------------- -------------- -------------- -----------
  Age (yr)                                                          0.994          0.973          1.008          0.294
  Male sex                                                          0.938          0.668          1.315          0.709
  Prior myocardial infarction                                       1.117          0.765          1.632          0.568
  Caucasian race                                                    1.105          0.908          1.345          0.314
  Prior percutaneous coronary intervention                          0.968          0.684          1.368          0.852
  Prior coronary artery bypass graft                                1.214          0.848          1.737          0.289
  Prior stroke                                                      1.595          0.994          2.561          0.051
  Prior peripheral artery disease                                   1.132          0.814          1.576          0.461
  Smoking history                                                   1.009          0.373          2.726          0.986
  Hypertension                                                      0.993          0.630          1.564          0.975
  Diabetes mellitus                                                 1.127          0.801          1.584          0.493
  History of infective endocarditis                                 1.539          0.381          6.217          0.542
  Permanent pacemaker                                               1.202          0.785          1.839          0.397
  Previous implantable cardioverter device                          1.089          0.481          2.468          0.837
  History of transient ischemic attack                              1.358          0.807          2.284          0.248
  Carotid artery stenosis                                           1.118          0.939          1.331          0.209
  Carotid artery stenting/endarterectomy                            1.373          0.762          2.481          0.292
  Currently on dialysis                                             2.694          1.491          4.868          \<0.001
  Moderate to severe chronic lung disease                           1.340          1.166          1.541          \<0.001
  Home oxygen                                                       2.073          1.336          3.216          \<0.001
  Atrial fibrillation/flutter                                       2.000          1.431          2.797          \<0.001
  Heart failure within 2-weeks                                      2.119          1.277          3.518          0.001
  Nyha class within 2-weeks                                         1.029          0.815          1.308          0.814
  Cardiogenic shock within 24 hours                                 0              0              Inf            0.583
  Cardiac arrest within 24 hours                                    0              0              Inf            0.501
  Left main stenosis ≥50%                                           1.362          0.871          2.129          0.174
  Proximal left anterior descending artery stenosis ≥70%            1.145          0.769          1.706          0.505
  Porcelain aorta                                                   1.262          0.739          2.156          0.393
  Society of thoracic surgeons risk score                           1.032          1.014          1.051          \<0.001
  Total albumin (g/dL)                                              0.431          0.294          0.631          \<0.001
  Vascular access site                                              1.143          0.925          1.413          0.215
  Balloon expandable valve                                          1.112          0.753          1.642          0.593
  Elective procedure                                                0.494          0.289          0.843          0.008
  Anesthesia                                                        0.734          0.443          1.226          0.237
  Mechanical assist device in place at the start of the procedure   1.264          0.764          2.091          0.357
  Ejection fraction (%)                                             0.992          0.982          1.004          0.221
  Aortic valve area (mm^2^)                                         0.764          0.437          1.336          0.346
  Aortic valve systolic mean gradient (mm Hg)                       0.994          0.982          1.006          0.356
  Moderate to severe                                                1.045          0.816          1.337          0.728
  Mitral regurgitation                                                                                           
  Moderate to severe tricuspid regurgitation                        1.449          1.221          1.721          \<0.001
  Moderate pulmonary regurgitation^\*^                              1.016          0.745          1.396          \<0.001
  Right ventricular systolic pressure (mm Hg)                       1.017          1.007          1.028          0.001
  Cardiac power index (W/m^2^)                                      0.027          0.008          0.093          \<0.001
  CP1                                                               0.030          0.016          0.057          \<0.001
  CP2                                                               0.066          0.037          0.117          \<0.001
  CP3                                                               0.252          0.158          0.401          \<0.001

CI, confidence interval; NYHA, New York Heart Association; CP, cardiac power.

^\*^No patients had severe pulmonary regurgitation.

###### Multivariate Cox Regression Results for 1-Year Mortality
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  Covariates                         Hazard ratio   95% CI lower   95% CI upper   *p* value
  ---------------------------------- -------------- -------------- -------------- -----------
  Cardiac power index (W/m^2^)       0.033          0.008          0.142          \<0.001
  Cardiac power index^\*^ (W/m^2^)   0.005          0.001          0.036          \<0.001
  CP1                                0.055          0.014          0.219          \<0.001
  CP1^\*^                            0.010          0.002          0.065          \<0.001
  CP2                                0.056          0.015          0.207          \<0.001
  CP2^\*^                            0.009          0.001          0.055          \<0.001
  CP3                                0.115          0.037          0.356          \<0.001
  CP3^\*^                            0.032          0.007          0.142          \<0.001

CI, confidence interval; CP, cardiac power.

Variables included in multivariate analysis: Currently on Dialysis, Moderate to Severe Chronic Lung Disease, Home Oxygen, Atrial Fibrillation/Flutter, Heart Failure within 2-weeks, Society of Thoracic Surgeons Risk Score, Total Serum Albumin, Elective Procedure, Moderate to Severe Tricuspid Regurgitation, Moderate Pulmonary Regurgitation.

^\*^Excluding patients with moderate to severe mitral regurgitation.
